Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels

Colorectal cancer (CRC) resistance to fluoropyrimidines and other inhibitors of thymidylate synthase (TS) is a serious clinical problem often associated with increased intracellular levels of TS. Since the tumour suppressor gene p53, which is mutated in 50% of CRC, regulates the expression of severa...

Descripción completa

Detalles Bibliográficos
Autores principales: Giovannetti, E, Backus, H H J, Wouters, D, Ferreira, C G, van Houten, V M M, Brakenhoff, R H, Poupon, M-F, Azzarello, A, Pinedo, H M, Peters, G J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360080/
https://www.ncbi.nlm.nih.gov/pubmed/17339891
http://dx.doi.org/10.1038/sj.bjc.6603639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360080/
https://www.ncbi.nlm.nih.gov/pubmed/17339891
http://dx.doi.org/10.1038/sj.bjc.6603639

Ejemplares similares